All In Biotech

Free tool

Medicare drug spending

CMS's Spending by Drug data: what Medicare paid for each drug before manufacturer rebates. Part D covers drugs dispensed by pharmacies; Part B covers drugs given in a doctor's office or hospital outpatient department. Commercial and list prices are not public data and are not shown.

Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations

Part D, 2024

$288.7B

Gross drug spending in the dataset

Part B, 2024

$60.8B

Gross drug spending in the dataset

Drugs listed

11

Part D and Part B

Total spending by year

  • Part D
  • Part B
View as table
YearPart DPart B
2020$194,092,038,339$37,778,829,680
2021$213,513,349,361$40,135,340,775
2022$239,779,215,689$44,241,259,745
2023$275,808,918,753$50,775,853,083
2024$288,667,842,058$60,838,164,403
Reset

Top 11 by total spending

2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.

DrugPartSpendingChangeBeneficiariesPer beneficiaryPer unit
Shingrix

Varicella-Zoster Ge/As01b/PF

D$776M-36%2,933,003$264$196.56
Savella

Milnacipran HCl

D$59.3M-3%16,606$3,572$7.96
Oxtellar XR

Oxcarbazepine

D$28.5M-9%2,844$10,008$17.96
Xcell amnio matrix, per square centimeter

· Q4280

B$26.8Mn/a211$126,979$1,951.25
M-M-R II Vaccine

Measles,Mumps,Rubella Vacc/PF

D$2.5M+65%20,979$117$103.86
Varivax Vaccine

Varicella Vaccine Live/PF

D$554K+9%2,659$208$173.88
Priorix

Measles,Mumps,Rubella Vacc/PF

D$230K+527%2,181$105$98.63
Activella

Estradiol/Norethindrone Acet

D$113K-9%57$1,991$9.60
Magellan Insulin Safety Syrng

Syringe,Needle,Insuln,Safe,1ml

D$13K-41%63$211$0.44
Ocella

Ethinyl Estradiol/Drospirenone

D$13K-55%97$130$0.64
Proquad

Measles,Mumps,Rub,Varicella/PF

D$10K+92%38$258$261.20

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.